Navigation Links
MicroConstants Completes Installation of Latest LC/MS/MS Technology to Achieve Improved Sensitivity in Bioanalytical Method Development
Date:3/2/2011

SAN DIEGO, March 2, 2011 /PRNewswire/ -- MicroConstants, Inc., a bioanalytical and pharmacokinetic-specialty Contract Research Organization (CRO) in San Diego, California, announces today that it has successfully completed the installation and qualification of a new Xevo® TQ-S tandem mass spectrometer from Waters Corporation. The unparalleled speed, sensitivity and accuracy of this new LC/MS/MS system will allow MicroConstants to quantify compounds at lower concentrations than previously possible and enable the development of more robust bioanalytical methods for even the most analytically complex compounds.

The Xevo® TQ-S tandem mass spectrometer was released in September of 2010 and this state-of-the-art LC/MS/MS system further increases the high sensitivity provided by the previous model, the Xevo® TQ MS, which MicroConstants acquired last June. The addition of this new system brings MicroConstants equipment count to a total of 16 LC/MS/MS systems at their San Diego bioanalytical laboratory.

When compared to earlier generation mass spectrometer models, MicroConstants experienced a forty fold increase in sensitivity with compounds tested internally in negative electrospray ionization mode. The significant increase in sensitivity can be attributed primarily to the system's new StepWave™ ion-transfer technology. This off-axis design dramatically increases the efficiency of ion transfer from the ion source to the quadrupole MS analyzer while at the same time actively eliminating undesirable neutral contaminants.

"Over the years, MicroConstants has gained a reputation for having the ability to develop bioanalytical methods for complex compounds when others have been unsuccessful in doing so," said David Beyerlein, vice president of global operations at MicroConstants. "This new LC/MS/MS system will allow our innovative method development team to improve methods and speed up method development for analytically complex compounds to help advance our clients' drug development programs."

About MicroConstants, Inc.

MicroConstants is a specialty Contract Research Organization (CRO) in San Diego, California that provides GLP-compliant bioanalytical research services, IND-enabling drug metabolism (DMPK) assays, ELISA immunoassay and pharmacokinetic analysis services to pharmaceutical and biotech companies developing new chemical entities worldwide. They specialize in method development, method validation and sample analysis of small molecules, proteins and peptides using LC/MS/MS, HPLC/UV and ELISA for preclinical and clinical drug development studies. For more information about MicroConstants and the contract research services they provide, please visit http://www.microconstants.com.


'/>"/>
SOURCE MicroConstants, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MicroConstants Now Offers Nanoparticle Formulation Services
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  Marking its ... accessible breast and ovarian cancer risk test, ... analyzing 30 genes that highly impact the most ... Available today, the Color Test analyzes hereditary cancer ... stomach, and uterine cancers. The Color Test is ...
(Date:4/28/2016)... 28, 2016  The blood testing market in ... to Kalorama Information and The Freedonia Group in a ... acid testing.  The healthcare research firm said that ... blood collection stations and in improving testing at the ... report, Blood Testing Market in China ...
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
Breaking Medicine Technology:
(Date:5/3/2016)... , ... May 03, 2016 , ... Elizabeth Murray has ... parrots to join her with one on her shoulder and one on her arm. ... parking lot because of years of mitral valve prolapse. , The valves of the ...
(Date:5/3/2016)... ... May 03, 2016 , ... Excessive panting in the ... pet anxiety. "Pet owners often think anxiety only manifests itself as trembling or ... other ways, and there’s things that be done about it,” says Dr. Jim Lowe, ...
(Date:5/3/2016)... ... 03, 2016 , ... Diagnotes, a leader in digital healthcare ... hospital system in South Carolina, to provide its secure mobile communication platform. , ... communication, drives workflow efficiencies and improves provider and patient satisfaction,” said Dr. Todd ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today announced ... medical situations or practice tricky or rare procedures in an environment that looks and ... Center is also available to inventors and “hackers” to develop and test new devices ...
(Date:5/3/2016)... ... May 03, 2016 , ... Each year, about 800,000 ... of death across the United States and account for one death every four minutes. ... or are permanently disabled. HCR ManorCare is launching a video series called “Your Brain,” ...
Breaking Medicine News(10 mins):